ArticleJournal of perinatology : official journal of the California Perinatal Association2026
Assessing the real-world effects of prophylactic hydrocortisone in the Canadian Neonatal Network: A cohort study.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of prophylactic hydrocortisone (pHCT) on the odds of death or moderate to severe bronchopulmonary dysplasia (BPD) in preterm neonates. STUDY
designMulti-center retrospective cohort study of infants born <28 weeks in the Canadian Neonatal Network 2019-2023 who received pHCT with 1:1 propensity score-matched controls. Hierarchical composite endpoints were explored using win odds analyses.
resultsThere were 361 infants per group with balanced baseline characteristics. There were no differences in the odds of death or moderate to severe BPD (pHCT 259/361 [71.8%] vs. control 264/361 [73.1%], OR 0.92, 95% CI [0.68, 1.24]). Win odds (95% CI) were not different: 1.02 (0.85, 1.28). There was lower use of systemic postnatal steroids and treatment of patent ductus arteriosus in the pHCT group; no significant differences in other safety outcomes were observed.
conclusionspHCT was not associated with reductions in mortality nor moderate to severe BPD.
Identifiers
42386902What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.